BAT Pauses U.S. Launch of Unlicensed Vuse One Vape amid FDA Crackdown — Reuters

Oct.28.2025

British American Tobacco has paused the U.S. pilot launch of its unlicensed Vuse One vape amid intensified FDA enforcement.

Editor’s Note

According to a Reuters report, British American Tobacco (BAT) has paused plans to launch an unlicensed disposable vape, Vuse One, in the United States amid intensified regulatory action by the U.S. Food and Drug Administration (FDA). BAT’s U.S. subsidiary, Reynolds American, decided to delay the pilot launch as the FDA accelerates enforcement against unapproved nicotine products and moves to streamline its licensing process.

On April 17, 2025, BAT’s subsidiary Reynolds American acquired 12 synthetic nicotine-based disposable vape products under the PACHA brand from Charlie’s Holdings, Inc., all of which have pending PMTA applications.

Key Points

BAT delays U.S. pilot launch: The company suspended its planned release of the Vuse One disposable vape, which lacks FDA authorization.

Regulatory pressure rising: The FDA has intensified actions against unlicensed vape products and reminded companies that selling unapproved nicotine products is unlawful.

Industry reactions: Philip Morris International and Altria are also navigating regulatory uncertainty as they test-launch nicotine pouch products without full FDA approval.

Strategic shift: BAT said it will focus on its existing nicotine portfolio while awaiting regulatory clarity.

References:

[1] Exclusive: BAT pauses unlicensed US vape launch as FDA action accelerates

Also Read:

[1] The U.S. Department of Justice and FDA seized 2.1 million e-cigarettes and 12 distributors and retailers were sued

[2] U.S. CBP and FDA Seize 165,000 Illicit E-Cigarette Products; Total Value Exceeds $1.47 Million

[3] Largest E-Cigarette Seizure in U.S. History: Over 600,000 Products Confiscated from Midwest Goods Warehouse; Company Denies Violations, Calls FDA “Unfair”

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com